Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 2,560 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 2,560 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total transaction of $81,408.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON opened at $29.93 on Wednesday. The firm has a market cap of $722.51 million, a price-to-earnings ratio of -8.58 and a beta of 0.18. The firm has a fifty day moving average price of $57.21 and a 200 day moving average price of $55.74. Disc Medicine, Inc. has a fifty-two week low of $21.70 and a fifty-two week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, March 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). As a group, research analysts predict that Disc Medicine, Inc. will post -4.44 earnings per share for the current year.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently bought and sold shares of IRON. Citigroup Inc. purchased a new position in Disc Medicine during the fourth quarter valued at $101,000. Geode Capital Management LLC purchased a new position in Disc Medicine during the fourth quarter valued at $540,000. ExodusPoint Capital Management LP purchased a new position in Disc Medicine during the fourth quarter valued at $601,000. Renaissance Technologies LLC purchased a new position in Disc Medicine during the fourth quarter valued at $258,000. Finally, Millennium Management LLC purchased a new position in shares of Disc Medicine in the 4th quarter worth $294,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IRON has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a report on Monday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a report on Wednesday, December 20th. Raymond James reaffirmed an “outperform” rating and set a $40.00 target price (down from $75.00) on shares of Disc Medicine in a report on Monday, April 1st. BMO Capital Markets reduced their target price on shares of Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, April 2nd. Finally, Stifel Nicolaus upped their target price on shares of Disc Medicine from $71.00 to $73.00 and gave the company a “buy” rating in a report on Monday, April 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.29.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.